Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

Elias Jabbour, Susan O'Brien, Xuelin Huang, Deborah Thomas, Michael Rytting, Koji Sasaki, Jorge Cortes, Guillermo Garcia-Manero, Tapan Kadia, Farhad Ravandi, Sherry Pierce, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Inotuzumab ozogamicin was found to be highly active in patients with refractory-relapsed acute lymphocytic leukemia (ALL), with an overall response rate of 58% and a median survival of 6.3 months. Identifying factors associated with different outcomes on inotuzumab therapy may help select patients for this treatment and advice of prognosis. A total of 89 patients treated with inotuzumab on previous studies were analyzed. Inotuzumab was given at 1.3-1.8 mg/m2 intravenously (IV) × 1 every 3-4 weeks or weekly (0.8 mg/m2 day 1, 0.5 mg/m2 days 8 and 15) every 3-4 weeks. Pretreatment factors associated with achieving marrow complete response (CR) and with survival were analyzed using standard statistical methods. The median survival of patients with at least marrow CR was 9.2 months versus 3.4 months for those without marrow CR (P<0.001). By multivariate analysis, a high peripheral blood absolute blast count and low platelet count were independently associated with a lower likelihood of achieving at least marrow CR. Baseline characteristics independently associated with worse survival included adverse cytogenetics [complex karyotype, translocation (4;11), translocation (9;22), abnormal chromosome 17], disease beyond first salvage, and high peripheral blood absolute count. Patients with 0, 1-2, or 3 adverse factors had a median survival of 39+, 7.5, and 2.4 months, respectively. Our current analyses identified a subset of adult patients with ALL in whom outcome of therapy with inotuzumab ozogamicin can be differentially predicted.

Original languageEnglish (US)
Pages (from-to)193-196
Number of pages4
JournalAmerican Journal of Hematology
Volume90
Issue number3
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal Antibodies
Bone Marrow
Survival
Chromosomes, Human, Pair 17
Platelet Count
Karyotype
Cytogenetics
Inotuzumab Ozogamicin
Therapeutics
Multivariate Analysis

ASJC Scopus subject areas

  • Hematology

Cite this

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. / Jabbour, Elias; O'Brien, Susan; Huang, Xuelin; Thomas, Deborah; Rytting, Michael; Sasaki, Koji; Cortes, Jorge; Garcia-Manero, Guillermo; Kadia, Tapan; Ravandi, Farhad; Pierce, Sherry; Kantarjian, Hagop.

In: American Journal of Hematology, Vol. 90, No. 3, 01.03.2015, p. 193-196.

Research output: Contribution to journalArticle

Jabbour, E, O'Brien, S, Huang, X, Thomas, D, Rytting, M, Sasaki, K, Cortes, J, Garcia-Manero, G, Kadia, T, Ravandi, F, Pierce, S & Kantarjian, H 2015, 'Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody', American Journal of Hematology, vol. 90, no. 3, pp. 193-196. https://doi.org/10.1002/ajh.23901
Jabbour, Elias ; O'Brien, Susan ; Huang, Xuelin ; Thomas, Deborah ; Rytting, Michael ; Sasaki, Koji ; Cortes, Jorge ; Garcia-Manero, Guillermo ; Kadia, Tapan ; Ravandi, Farhad ; Pierce, Sherry ; Kantarjian, Hagop. / Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. In: American Journal of Hematology. 2015 ; Vol. 90, No. 3. pp. 193-196.
@article{c001e34bd72544c5b26172c07bd1d7f0,
title = "Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody",
abstract = "Inotuzumab ozogamicin was found to be highly active in patients with refractory-relapsed acute lymphocytic leukemia (ALL), with an overall response rate of 58{\%} and a median survival of 6.3 months. Identifying factors associated with different outcomes on inotuzumab therapy may help select patients for this treatment and advice of prognosis. A total of 89 patients treated with inotuzumab on previous studies were analyzed. Inotuzumab was given at 1.3-1.8 mg/m2 intravenously (IV) × 1 every 3-4 weeks or weekly (0.8 mg/m2 day 1, 0.5 mg/m2 days 8 and 15) every 3-4 weeks. Pretreatment factors associated with achieving marrow complete response (CR) and with survival were analyzed using standard statistical methods. The median survival of patients with at least marrow CR was 9.2 months versus 3.4 months for those without marrow CR (P<0.001). By multivariate analysis, a high peripheral blood absolute blast count and low platelet count were independently associated with a lower likelihood of achieving at least marrow CR. Baseline characteristics independently associated with worse survival included adverse cytogenetics [complex karyotype, translocation (4;11), translocation (9;22), abnormal chromosome 17], disease beyond first salvage, and high peripheral blood absolute count. Patients with 0, 1-2, or 3 adverse factors had a median survival of 39+, 7.5, and 2.4 months, respectively. Our current analyses identified a subset of adult patients with ALL in whom outcome of therapy with inotuzumab ozogamicin can be differentially predicted.",
author = "Elias Jabbour and Susan O'Brien and Xuelin Huang and Deborah Thomas and Michael Rytting and Koji Sasaki and Jorge Cortes and Guillermo Garcia-Manero and Tapan Kadia and Farhad Ravandi and Sherry Pierce and Hagop Kantarjian",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/ajh.23901",
language = "English (US)",
volume = "90",
pages = "193--196",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

AU - Jabbour, Elias

AU - O'Brien, Susan

AU - Huang, Xuelin

AU - Thomas, Deborah

AU - Rytting, Michael

AU - Sasaki, Koji

AU - Cortes, Jorge

AU - Garcia-Manero, Guillermo

AU - Kadia, Tapan

AU - Ravandi, Farhad

AU - Pierce, Sherry

AU - Kantarjian, Hagop

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Inotuzumab ozogamicin was found to be highly active in patients with refractory-relapsed acute lymphocytic leukemia (ALL), with an overall response rate of 58% and a median survival of 6.3 months. Identifying factors associated with different outcomes on inotuzumab therapy may help select patients for this treatment and advice of prognosis. A total of 89 patients treated with inotuzumab on previous studies were analyzed. Inotuzumab was given at 1.3-1.8 mg/m2 intravenously (IV) × 1 every 3-4 weeks or weekly (0.8 mg/m2 day 1, 0.5 mg/m2 days 8 and 15) every 3-4 weeks. Pretreatment factors associated with achieving marrow complete response (CR) and with survival were analyzed using standard statistical methods. The median survival of patients with at least marrow CR was 9.2 months versus 3.4 months for those without marrow CR (P<0.001). By multivariate analysis, a high peripheral blood absolute blast count and low platelet count were independently associated with a lower likelihood of achieving at least marrow CR. Baseline characteristics independently associated with worse survival included adverse cytogenetics [complex karyotype, translocation (4;11), translocation (9;22), abnormal chromosome 17], disease beyond first salvage, and high peripheral blood absolute count. Patients with 0, 1-2, or 3 adverse factors had a median survival of 39+, 7.5, and 2.4 months, respectively. Our current analyses identified a subset of adult patients with ALL in whom outcome of therapy with inotuzumab ozogamicin can be differentially predicted.

AB - Inotuzumab ozogamicin was found to be highly active in patients with refractory-relapsed acute lymphocytic leukemia (ALL), with an overall response rate of 58% and a median survival of 6.3 months. Identifying factors associated with different outcomes on inotuzumab therapy may help select patients for this treatment and advice of prognosis. A total of 89 patients treated with inotuzumab on previous studies were analyzed. Inotuzumab was given at 1.3-1.8 mg/m2 intravenously (IV) × 1 every 3-4 weeks or weekly (0.8 mg/m2 day 1, 0.5 mg/m2 days 8 and 15) every 3-4 weeks. Pretreatment factors associated with achieving marrow complete response (CR) and with survival were analyzed using standard statistical methods. The median survival of patients with at least marrow CR was 9.2 months versus 3.4 months for those without marrow CR (P<0.001). By multivariate analysis, a high peripheral blood absolute blast count and low platelet count were independently associated with a lower likelihood of achieving at least marrow CR. Baseline characteristics independently associated with worse survival included adverse cytogenetics [complex karyotype, translocation (4;11), translocation (9;22), abnormal chromosome 17], disease beyond first salvage, and high peripheral blood absolute count. Patients with 0, 1-2, or 3 adverse factors had a median survival of 39+, 7.5, and 2.4 months, respectively. Our current analyses identified a subset of adult patients with ALL in whom outcome of therapy with inotuzumab ozogamicin can be differentially predicted.

UR - http://www.scopus.com/inward/record.url?scp=84923071079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923071079&partnerID=8YFLogxK

U2 - 10.1002/ajh.23901

DO - 10.1002/ajh.23901

M3 - Article

C2 - 25407953

AN - SCOPUS:84923071079

VL - 90

SP - 193

EP - 196

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -